(Total Views: 459)
Posted On: 02/12/2020 2:21:42 PM
Post# of 154900
Merck's Keytruda meets PFS endpoint in TNBC study
Feb. 12, 2020 6:57 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355, evaluating the combination of Keytruda (pembrolizumab) and chemo in patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score at least 10) met one of the dual primary endpoints, progression-free survival (PFS).
In a first-line setting, treatment with the Keytruda combo resulted in a statistically significant increase in PFS compared to chemo alone.
The trial will continue unchanged in order to assess the other primary endpoint of overall survival (OS).
https://clinicaltrials.gov/ct2/show/NCT02819518
Feb. 12, 2020 6:57 AM ET|About: Merck & Co., Inc. (MRK)|By: Douglas W. House, SA News Editor
Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355, evaluating the combination of Keytruda (pembrolizumab) and chemo in patients with metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score at least 10) met one of the dual primary endpoints, progression-free survival (PFS).
In a first-line setting, treatment with the Keytruda combo resulted in a statistically significant increase in PFS compared to chemo alone.
The trial will continue unchanged in order to assess the other primary endpoint of overall survival (OS).
https://clinicaltrials.gov/ct2/show/NCT02819518
(0)
(0)
